On September 27, 2017 the Supervisory Board of STADA Arzneimittel AG appointed Dr. Claudio Albrecht as new Chairman of the Executive Board with immediate effect. Dr. Albrecht succeeds Engelbert Coster Tjeenk Willink who had held the office of Chairman of the Executive Board on an interim basis since July 4, 2017. Mark Keatley will take over the position of Chief Financial Officer from his interim predecessor Dr. Bernhard Düttmann, also with immediate effect. Dr. Barthold Piening, Chief Technical Officer at STADA, will keep his position on the Executive Board.

“We are extremely pleased that we have been able to attract Dr. Claudio Albrecht and Mark Keatley, two managers with extensive experience in the international pharmaceutical and generics industry. With their expertise, they are exactly the right people to move the transformation process that has already been initiated forward and to help STADA sustainably achieve more growth”, says Chairman of the Supervisory Board Dr. Günter von Au. “We would like to express our sincere thanks to Mr. Willink and Dr. Düttmann for leading STADA through a very important phase and for taking the company another step in the right direction with their extraordinary level of commitment.”

“STADA is a company rich in history, with highly-motivated employees and tremendous potential”, says Dr. Albrecht, new Chairman of the Executive Board. “Together, we will work toward making STADA more efficient and expanding it into a major international group.”